Paul Basciano

Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder

Theodore E. Warkentin, Paul Basciano, Jared Knopman et al. · Blood · 2014 · 157 citations · Full text

Medicine, Hematology, Pathology +11

Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration

JB Bussel, C. S. Lee, Caroline Seery et al. · Haematologica · 2014 · 96 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +7

Abstract CT116: BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial

Lillian L. Siu, Karen A. Gelmon, Quincy S. Chu et al. · Cancer Research · 2017 · 86 citations

Medicine, Oncology, Pharmacology +17

Abstract CT180: Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors

Lillian L. Siu, Howard A. Burris, Dung T. Le et al. · Cancer Research · 2018 · 64 citations

Pharmacy, Oncology, Pharmacology +17

BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).

Jason J. Luke, Josep Tabernero, Anthony M. Joshua et al. · Journal of Clinical Oncology · 2019 · 57 citations

Pharmacy, Pharmacology, Pharmacotherapy +17